7-8 SEPTEMBER 2022 (WED-THU) AUDITORIUM PERDANA, NATIONAL INSTITUTES OF HEALTH, SETIA ALAM organized by
FOREWORD Selangor State's Health Director YBhg. Dato’ Indera Dr. Sha’ari bin Ngadiman It is with great contentment that I extend my welcome to all duteous participants to the Inaugural Selangor Research Conference 2022 and the 9th Selangor Research Day. Resonating along the conference’s theme; Technology-Driven Research -The Way Forward, we are truly experiencing the revolution of digital health pertaining to healthcare in recent days. This conference has a dignified aim of creating a platform for all researchers to present their research findings as well as to learn new knowledge in the field of research. It also lays a path for researchers with the latest perspectives on integrating technology in research as well as networking opportunities with similar-minded people. As I've been informed, this year, this event is being organized physically following two years of the COVID-19 pandemic. The pandemic has been an eye-opener and has given rise to importance concerning our healthcare. I proudly say, despite being under the threat of COVID-19, we were pushed to make an avant-garde approach to strongly adopt digital healthcare technology on a large scale. Under the pressure circumstances that fabricated our healthcare system and through its predicament, we persevered. We have made significant improvements and innovations to overcome the challenges, including the introduction of the MySejahtera App, digital initiatives such as home monitoring systems, and public-private partnerships to deliver vaccinations nationwide. In line with the advancement of technology and innovation, and under our government’s 12th Malaysia Plan, the allocation of research funding has been made to be one of our national priorities. This is also an effort taken that is blooming to produce more locally emerging technology developers that are health sector-driven. Hence, changing the niche into a norm where performing research via digital health tech is encouraged in our healthcare system. I highly prophesy that this platform chaired by the Clinical Research Center of Hospital Sungai Buloh will bear an eye- opening, reassuring and accessible path to our conscientious participants to help improve our healthcare system to its highest potential. It is my fervent hope that knowledge and ideas from our respected plenary speakers and presenters will help us deepen our knowledge in the world of research amid these inevitable waves of pandemic changes. I would like to express my sincere appreciation and gratitude to each and everyone involved in putting together this valuable conference. I thank the organizing committee and volunteers for providing a valuable platform to us all to gather and learn together. Thank you.
FOREWORD Advisor, Selangor Research Conference and Head, CRC Hospital Sungai Buloh Mr. Liew Boon Seng On behalf of the CRC, Hospital Sungai Buloh, it is my great honor to welcome all of you to our long-awaited Inaugural Selangor Research Conference 2022 and the 9th Selangor Research Day. First and foremost, how the theme Technology-Driven Research – the Way Forward will resonate at the conference, you may wonder. In the past few years, we’ve undoubtedly witnessed that the adoption of technology has led to tremendous improvements in our lives. Definitively, healthcare is one of the sectors that has benefited the most. Scientific discoveries and scientific hypotheses undergo major changes under different circumstances. For example, from Karl Popper’s perspective, technologies modify scientific prospects while observations induce scientific revolutions. Thanks to new technologies, we now live in a new revolutionary period I firmly believe that technology and humans should be closely associated for better healthcare, moving forward. Collaboration between people and technology has resulted in prodigious achievements, notably in medicine and healthcare. And I strongly believe that research and the world of digital technology can transform unsustainable healthcare systems into sustainable ones. The circumstances that we had during our time handling COVID-19 have surprisingly opened other doors to some unthinkable innovative solutions and certainly utilizing digital technology was one of them. But what does technology have to do in terms of Research and Healthcare? And what could be the ground-breaking medical technologies in healthcare right now? How can research be integrated with technology? With these questions in mind, I look forward to your curiosity to be fed with valuable learning and experience through this conference. Looking at the topics prepared by our plenary speaker, I am optimistic that this is legitimately achievable. Henceforth, I would like to extend my deepest gratitude to our plenary speakers for their time, hard work, and commitment to attending our event. We appreciate the support we have received from all our participants, poster, and oral presenters, our esteemed plenary speakers, and all our devoted judges. Without your support, this event would not have been possible. Having said so, I aspire every attendee to avail of this conference as much as possible. At at the same time, to take the opportunity to build more future collaborations and forge networking. Thank you.
FOREWORD Director, Institute for Clinical Research (ICR) Prof. Datuk Dr. Kalaiarasu M. Peariasamy On behalf of the organizers, I wish to extend a warm welcome to all attending the Selangor Research Conference 2022 and the 9th Selangor Research Day, September 7 – 8 at the National Institutes of Health (NIH) with the theme; Technology-Driven Research – the Way Forward. Advancement in health technology is rapidly revolutionizing the delivery of healthcare through digital solutions, innovations, and cutting-edge treatment. We have seen Ai driven medical applications implemented for data collection, novel treatments, remote monitoring for favourable patient outcomes. ICRis excited with the newly established DHRi Unitdriving various research in the pandemic era using artificial intelligence, big data analytics,modelling, mobile apps, 3D printing and VR technology. This new area of research augurs well for our future healthcare development in advancing medical technology to embrace personalised care at the community level. Our vision for this conference is to spread knowledge in the current technological era. Let us value this by harnessing as much comprehension as possible and nurturing it in our respective fields.I extend my thanks to all plenary speakers and wish all an enjoyable conference. Thank you.
FOREWORD Director, Hospital Sungai Buloh Dr Kuldip Kaur A/P Prem Singh K.M.N I am at my utmost excitement to welcome all of you to this distinguished event organized by our committed CRC of Hospital Sungai Buloh. With the theme of this conference in mind, it is undoubtedly proven that technology in healthcare is a new, growing epitome that is ground-breaking new medical technologies. Technological development is unstoppable. The increase in fundamental knowledge concerning human health and the mechanisms of disease has been so rapid during the second half of this century that we have often been described as living in a time of biological revolution. I beg to differ that the true essence of progress is in the application of scientific knowledge for enhancing the human condition. Malaysia and the research community, for the past several decades, have valued biomedical innovation and its promise of improving the management of health and disease. Rapid advances in medical research have indeed stimulated the development of numerous efficacious medical technologies before we even know it. Taking the best advantage of this evolving research technology and fully implementing it into our healthcare system will no longer be science fiction but instead an achievable reality. On reflection, given the centuries of stability, it is astonishing how much healthcare has changed in the last 150 years – and one wonders how this accelerating pace of change will proceed in the future. Finally, I would like to extend my appreciation to the Clinic Research Center of Hospital Sungai Buloh and all the committee members for organizing this conference and ensuring that it proceeded smoothly. I foresee this event will generate a mindset of innovation and creativity and trigger our curiosity. And as we all fathom, through curiosity, innovation begins. Thank you.
FOREWORD Scientific Chairperson, Selangor Research Conference and Head, CRC Hospital Rehabilitasi Cheras Dr. Chern Phei Ming Firstly, I am delighted to extend my gratitude to each of our plenary speakers for partaking and sharing your valuable knowledge with the younger generation of professionals here today. I take pride in being the head of the Scientific Committee this year and I am proud to be collaborating with an outstanding team from all various walks of profession. I also want to thank all of you for connecting this morning, and I hope you are looking forward to the discussions as much as I am. As we gathered today, with the theme of ‘Technology-Driven Research – the Way Forward', the healthcare industry has evolved immensely over the years, and much of that change has been driven by technology. Technology-driven innovation holds the potential to improve our understanding of patients and enable the delivery of more convenient, individualized care. This shouldn’t have happened without the massive growth of AI-driven technologies and digitization of healthcare workflows, as a response to more savage global conditions, as well as the rising demand for accessible and quality medical services. Tech-infused tools are being integrated into every step of our healthcare experience to counteract two key trouble spots: quality and efficiency. The way we purchase healthcare is becoming more accessible to a wider group of people through the insurance technology industry, sometimes called \"insurance.\" Patient waiting times are declining and hospitals are more efficiently staffed thanks to artificial intelligence and predictive analytics. Even surgical procedures and recovery times are being reduced thanks to ultra-precise robots that assist in surgeries and make some procedures less evasive. Research on and evaluation of digital health outcomes and impact are essential to support its safe implementation, establish and promote accountability, and to justify the financial investment. The agenda should also address the need to stimulate the development and testing of technologies, methods, and infrastructures that overcome obstacles to the application of digital health to health priorities. We are very much astonished by our newfound capabilities. Slowly but surely, our digital age begins to array its pathways to our healthcare making revolutionary medical capabilities and breakthrough treatment opportunities. Even so, I could very much say that we are still in our infancy stage. We must have the urgency to keep up with the latest trends in health tech like other innovative countries in an effort to chase our goals forward. I am eager to hear from our plenary speakers about their insights and our presenters' compound findings of their accredited research in the next two days. I hope we can further optimize our time here and learn some of the most prominent ways technology in healthcare is making an impact on today’s medical system. On that note, let me once again thank the organizing committee, scientific committee, fantastic volunteers, and all for giving their time and dedication to making this event a success. Thank you.
FOREWORD Organizing Chairperson, Selangor Research Conference & Manager, CRC Hospital Sungai Buloh Dr. Swarna Lata Krishnabahawan On behalf of the Clinical Research Centre of Hospital Sungai Buloh and as the Organizing Chair, I do hereby welcome the honorable VIPs, distinguished Speakers, esteemed Judges, Presenters, Delegates, Students, and Guests to grace the occasions of the Inaugural Selangor Research Conference 2022 and the 9th Selangor Research Day. We are proud to have eminent support from all our sister CRCs and network who have come together in making this conference a success. It our priviledge to organize this conference after the pandemic; with a theme that is apt for this period; ‘Technology Driven Research – the Way Forward.' I would like to thank the committee members, our other sponsors, well-wishers and to all those who have given their active support to organize this conference. I believe this conference will add another feather to the historical book of the Research fraternity. Once again, i welcome you all to our Inaugural Research Conference 2022 and the 9th Selangor Research Day. I hope you will have a very exciting and enriching academic sessions for two days. Thank you.
PLENARY 1 Dr. Khor Swee Kheng Master of Public Policy, University of Oxford, UK 2020 Master of Public Health, University of California, Berkeley 2016 Membership, Royal College of Physicians of the UK 2011 Doctor of Medicine, National University of Malaysia (UKM) Co-Founder & CEO. Angsana Health, Southeast Asia Assistant Professor. National University of Singapore Since Mar 2022 Associate Fellow. Chatham House, United Kingdom Senior Visiting Fellow. United Nations University International Institute for Global Health Visiting Fellow. Institute of Strategic and International Studies (ISIS) Malaysia Co-Founder. Malaysian Health Coalition (comprising 52 professional societies) Columnist & Lecturer (>180 publications in academic journals, think-tanks and media) Chair. Healthcare Working Group, ASEAN Business Advisory Council Since May 2021 Consultant. Various Organizations Ethics & Compliance Director, East Europe, Middle East & Africa. AbbVie, Paris, France 2017- 2019 Director, Middle East & Africa. AbbVie, Dubai, UAE 2016-2017 Director, China. AbbVie, Shanghai, China 2016 Associate Director, Middle East & North Africa. AbbVie, Dubai, UAE 2013-2016 • People: Multiple promotions. Ultimately led a multinational team of 20 Compliance Directors, Managers & Liaisons across EEMEA, with an annual operating budget of ~$2.3 million (2017-9). • Geography: Responsible for Central & Eastern Europe, Russia, Ukraine, Central Asia, the Middle East & Africa (“EEMEA”). Supported ~$1.1 billion annual revenue and ~1800 employees based in >70 countries. • Start-Up: Built seven Compliance Programs in MEA (2013-4). Built separate Monitoring and Training Programs for EEMEA (2014-5). Built an International Compliance Policy Program for all countries (except USA, 2016-8). • Industry Leadership: Represented AbbVie to General Assemblies of industry associations (EFPIA Brussels, PhRMA MEA, RDPAC China, and SAPI Singapore, 2012-9). Chair of the PhRMA Gulf Ethics Committee (2014-6). Medical Manager. Abbott Laboratories, Singapore 2011-2012 • Governance: Member of Senior Management Team. Led interactions with doctors, payers & regulators in 15 therapeutic areas. Responsible for Pharmacovigilance, Risk Management, Medical Information & Materials Review. • Research: Launched six Phase 3 RCTs (from site feasibility to start-up and monitoring), double the previous rate. Achieved the highest ratings for Pharmacovigilance and Good Clinical Practice Audits. • Access: Provided scientific, public health, and policy support for five new product or indication launches (2010-2). Active member of pricing negotiations for HIV/AIDS medicines with Singapore public hospitals and Centre for Disease Control (2011-2). Delivered Singapore’s first Payer Access Forum in Immunology, involving academics, policymakers and physicians from Singapore, Canada and the United States (2012). Awards English Debate Team Captain and Coach, National University of Malaysia 2001-2005 Team Awards: Four-time National Malaysian Champion (2002-2005). Malaysia’s first ESL World Champion (2005). Individual Awards: Royal Malaysian Intervarsity Tournament Top Speaker (2003). WUDC World Championships ESL Third Best Speaker (2004). Malaysian Debating Union Achievement Award (2005). Coaching Success: Coached one National University Champion team (2003) and one State High School Champion team (2007). Also coached >100 debaters in two universities and four high schools (2002-2010). The Scouts Association of Malaysia 1994-2000 King’s Scout. Malaysia’s highest Scouting Award (1998). (Equivalent to UK’s Queen’s Scout or USA’s Eagle Scout).
Plenary 1 A Health Systems View of Research Abstract Clinical research is the fundamental building block of evidence-based medicine, which is the fundamental building block of healthcare. However, the traditional model of clinical RCTs is increasingly supplemented by non-clinical real-world evidence, patient-reported outcomes and Big Data/AI/ML. Researchers using old and new research tools may benefit from integrating a health systems view into their work, by bringing together clinical, patient- reported, economic, equity, population health, policy and service delivery outcomes in an inter-disciplinary approach.
PLENARY 2 Professor Dr. Tan Geok Chin PhD degree at Imperial College London Professor and Consultant Anatomical Pathologist Deputy Dean, Research and Innovation Faculty of Medicine, Universiti Kebangsaan Malaysia Department of Pathology Hospital Canselor Tuanku Muhriz, Universiti Kebangsaan Malaysia IDr Tan Geok Chin is a Professor of Pathology, and Consultant Anatomical Pathology at Faculty of Medicine. He is currently the Deputy Dean of Research and Innovation of the Faculty of Medicine, UKM. He received his training in anatomical pathology in the National University of Malaysia and subsequently received his PhD degree at Imperial College London where he studied the characteristics of microRNA isomers in Stem Cells. His work led to the discovery of diverse function of isomiRs and their evolutionary importance and it was published in Nucleic Acid Research. Subsequently, he completed the Paediatric Pathology Fellowship training in Nationwide Children’s Hospital, Columbus, Ohio, USA. He is currently a member of the medical ethics committee in UKM and the Editor-in-Chief of the Malaysian Journal of Pathology. He has received multiple excellent service awards (2007 and 2019), including Best article award from Medical Journal of Malaysia and Best Poster Award from Royal Society, Edinburgh. He is a fellow of the Academy of Medicine Malaysia and holds a number of positions in the College of Pathologists and Malaysia Medical Council. He is a member of the credentialing committee of Anatomical Pathology, MMC. He is a member of the education committee and continuous professional development (CPD) committee of the CPath, AMM. He is the treasurer of the Chapter of Perinatal and Paediatric Pathology, CPath. He is a member of Perinatal and GUT Research Groups in the faculty. His current research interest is in Paediatric and Perinatal Pathology, wiAtwha rads number of on-going projects, namely gene expression of hydatidiform mole, chorioamnionitis and its correlation with neonatal outcomes, and GUT microbiome of neonates.
Plenary 2 Precision Medicine vs Personalised Medicine Abstract The term “personalised medicine”means tailoring of medical treatment tothe individual characteristics of each patient, leading to a treatmentapproach of “the right drug, for the right patient, at the right time.”The terms precision medicine and personalised medicine have been used interchangeably. However, personalized medicine is the older term. Actually, precision medicine is the prefer term, asthe focus is on identifying which approaches will be effective for which patients based on genetic, environmental, and lifestyle factors. One of the examples is pharmacogenomics whichcombines pharmacology (the study of drugs) and genomics (the study of genes) to develop effective, safe medications and doses tailored toa person’s genes. In cancer targeted therapy, thedetection of specific molecular markers that are found only on certain types of cancer, can be used to treat cancer more effectively. For example, the presence of HER2 gene amplification in breast cancer (seen in 20% of cases, a more aggressive phenotype), can be treated by Trastuzumab (Herceptin), a monoclonal antibody with excellent outcome. The implementation required a multi-disciplinary approach involving, surgeons, oncologists and pathologists. Stem cells and regenerative medicine is another form of precision medicine. By isolating and manipulating an individual stem cells, it could be used to repair a damage organ of that individual. CAR-T therapy and PDL1 are some of the others recently established forms of precision medicine. Many researchers are investigating the role of gut microbiome in regulating our health status and brain function, and the to understand the benefit of introduction of probiotics to improve gut bacterial flora. Currently, molecular testing is still very expensive and many are not able to receive this treatment.In conclusion,to improve healthcare in the country, everyone should be given the opportunity to precision medicine therapy.
PLENARY 3 Professor Datuk Dr. Kalaiarasu M Peariasamy BDS (Mal), MSc (Lond), MPaedDentRCS (Eng), MPaedDentRCPS (Glasg), CCST (UK), FDSRCS (Eng), FCSRCPS (Glasgow), FDSRCS (Edinburgh) Director of Institute for Clinical Research (ICR), NIH, MOH Malaysia Chairman of Jawatankuasa Kecil Pemilihan Calon Vaksin COVID-19 KKM Senior Consultant in Paediatric Dentistry Scientific Reviewer for Medical Research Ethics Committee Dr Kalaiarasu has served in civil services for more than 35 years and have contributed tremendously in the field of Paediatric Dentistry and the field of research. His main areas of interest is cleft lip and palate and surgical repair and care, paediatric dento-facial trauma and oral surgery. He has also contributed as an author in a few chapters in Cleft Lip and Palate in Children book and involved in the publication of the Clinical Practice Guidelines for Ministry of Health, Malaysia. Till date, he has published/presented more than 30 articles/papers in his field of interest. He is often invited as a speaker and has given many lectures in paediatric dentistry as well as presenting at several international conferences. He has received many distinguished awards from local and international organisations. He also plays a key role in developing the National COVID-19 Vaccination Programme by Ministry of Health, Malaysia. Awards Tokoh Kesihatan Pergigian Negeri Sabah-2005 Anugerah Perkhidmatan Cemerlang Jabatan Kesihatan Negeri Sabah- 2003 Ahli Mahkota Terengganu-1997
Plenary 3 ICR as the Pillar in Establishment of Research Culture Abstract The Institute for Clinical Research (ICR), previously known as the National Clinical Research Centre, Ministry of Health Malaysia was founded more than 20 years ago. The research areas mainly focus on clinical trials, clinical epidemiology, digital health and patient related outcomes. For an institution to improve its research culture, the most important considerations are to reflect on its organisational values and purpose. ICR’s research culture is driven by research that matters to patients and to support evidence-based clinical practice founded on ethical conduct of research, data integrity and scientific validity. Whilst obstacles to developing a research culture can come in many forms, it is important that solutions are identified and implemented. For that, ICR developed a strategic framework with defined pillars of excellence in a) Clinical Research Hub, b) Technology in Clinical Research, c) Sustainable Human Capacity Building and d) Visibility. Further, the working environment reflected the concepts of research freedom, use of advanced scientific approaches, and encouraged high inflow of young talented researchers. In addition, researchers’ funding requirements from internal and external grants, access to infrastructure, academic training, research collaboration within and beyond the organization were facilitated. Arguably, transforming research culture is complex, and developing a strategic framework and implementing it well most certainly helps to drive research excellence of national and international relevance.
PLENARY 4 Associate Professor Dr. Chong Chun Wie BSc (HONS) Biochemistry and PhD (Molecular Microbiology) Background Data Science Consultant, AMILI PTE. LTD. Sep 2020 Research Fellow, Universiti Perubatan Antarabangsa (International Medical University) 2019 Introduction Dr Chong Chun Wie obtained his BSc (HONS) Biochemistry and PhD (Molecular Microbiology) from the University of Malaya. After his PhD, he worked briefly at the National Antarctic Research Centre, University of Malaya briefly as a Post-Doctoral Research Fellow. He joined the School of Pharmacy, IMU in 2012. During his tenure, he was appointed as the Programme Director of MSc Molecular Medicine and Head, Centre of Translational Research. After 7 years with IMU, Dr Chong joined the School of Pharmacy, Monash University Malaysia in July 2019. His main research focus is on the microbial ecology of soil and gastrointestinal systems. He is experienced in processing large metagenomic datasets and conducting multivariate data analyses including hypothesis testing, ordinations and modelling.
Plenary 4 Managing Prediabetes through Digital Health and Pharmacy-supported Program Abstract Pre-diabetes is defined as an intermediate state of hyperglycaemia with glycaemic parameters above normal but below the T2DM threshold. It was estimated that >25% of pre-diabetic individuals convert to T2DM within 3-5 years, and 70% of individuals with pre-diabetes will develop into full-fledge T2DM within their lifetimes. In Malaysia, the prevalence of prediabetes is estimated to be around 20-30%. There is an urgent need to address this issue to reduce the diabetes burden in the country. Leveraging the advancement of digital health technology and the readily available large network of community pharmacies, our team is piloting a digitally supported prediabetes intervention program in the community pharmacy. Our preliminary results suggested that the participants are ready to embrace mobile apps to manage their personal health. The project also enables community pharmacists to play a bigger role in chronic disease management in Malaysia.
PLENARY 5 Professor Datuk Dr. Lekhraj Rampal PMW, AMP, PPT, MBBS, MPH, DrPH, FAMM, FAMS, FASc, FRSH, FPHMM Professor, Universiti Putra Malaysia Editor in Chief, The Medical Journal of Malaysia (MJM) Editor in Chief, Commonwealth Medical JournalObtained his MBBS in 1972, Master of Public Health in 1978, Doctorate of Public Health in 1988. Certificate in Cancer Epidemiology in 1986, . Certificate in Applied Epidemiology in HIV/ AIDS Course from CDC, Atlanta USA in 1992. He is a Fellow Academy of Medicine Malaysia (1997), Fellow of the Academy of Medicine Singapore (2011), Fellow Academy of Science Malaysia (2019), Fellow of Public Health Medicine Malaysia (2012) and Fellow Royal Society of Health London (1979). edf He has served in UPM in various committees such as Research Committee, Ethics Committee, Curriculum Development Committee, Examination Committee etc.. He has provided consultancy services to more than 300 Medical student research projects and 50 post graduate students. He has supervised 23 PhD and 28 Master students who have graduated. He has completed more than 90 Research projects. He has served as the Program Head of IRPA MOSTE Research Grant (RM 6,490,500.00) IRPA No. 06-02-04-0000-PR0041/05 (2005 – 2009). Published more than 150 articles in peer reviewed journals including in Lancet, Nature, The Lancet Diabetes and Endocrinology, eLife. His Google Scholar H Index is 36 with 20,380 citations (Scopus h index 24 with 12,223 citations). He is listed in the World's Top 2% Scientists. He is also the President, Malaysian Council for Tobacco Control (2018-2022). He served as the President, College of Public Health Medicine, Academy of Medicine Malaysia (2009-2014), Member of WHO. FCTC Steering Committee Malaysia at National Level, MOH (since 2018), Member of the Task Force for the proposed new Tobacco and Smoking Control Act, MOH, Member of the Expert Panel for the Parliament Select Committee for Health, Science and Innovation for the proposed new Tobacco and Smoking Control Act., Chairman, Action on Smoking and Health Committee MMA (since 2014). He was Member of Specialist Sub Committee of Public Health, National Specialist Register 2008-2018 (Chairman 2012-2014). He has served as the Course Director: W.H.O. Training Course for Supervisory Skills in Diarrheal Diseases (CDD)/ Acute Respiratory Infections (ARI ) Program) in 1990, Course Facilitator for W.H.O. Training Course for Managers of National Program for CDD and ARI in 1992, Head, (in charge of National HIV/AIDS Training Program, National CDD and ARI Training Program (1989-1993); Deputy Chairman, Malaysian Health Promotion Board (2007-2010) and Chairman, Public Health Society (1998- 2009), Member Board of Management Malaysian Professional Centre (2006-2008). He is the Editor in Chief, The Medical Journal of Malaysia (since 2014), Editor in Chief, MJM Case Reports Journal (since 2021), Editor in Chief, Commonwealth Medical Journal (2021-2024), Chairman of the MASEAN Group of Journals (2018-2022). He has served as Editor in Chief, Malaysia Journal of Medicine and Health Sciences (2013-2016). He has also served as Temporary Advisor and Short-Term Consultant with W.H.O. He has a keen interest in Non- Communicable Disease (NCD). He has Chaired several Committees at National level. He has been an external Examiner for post graduate (PhD and Master) students for USM and PhD Students UM and Monash University, Australia, MSc students for Royal College of Surgeons in Ireland and University College Dublin, Penang. He has been a Panel member for Malaysian Qualifications Agency for accreditation academic programs for Masters and Doctorate in Public Health program. He has been the Chairman, Scientific Committee of 1st, 2nd and 3rd Asia Pacific Conference on Public Health in 2004, 2007, and 2015. Awards He has also received several awards including the title ‘Datuk’ from DYMM Seri Paduka Baginda Yang di-Pertuan Agong in 2017 the Ahli Mahkota Perak in 2015; Pingat Pekerti Terpilih from Selangor in 1981 and Pingat Jasa Kebaktian from Selangor in 1979. He has also received several other awards including the Excellent Service Award Universiti Putra Malaysia 2006, 2007, 2008, 2012, 2013, 2014, 2015 and 2016. In 2014, he was awarded the Gold Medal (Highest Medal) by Malaysian Medical Association (MMA) for the outstanding contribution to the Nation building, MMA Outstanding Public and Healthcare Services Award, Blue Ribbon Award (individual Category) for the outstanding achievement in advocacy of smoke free environment by Minister of Health (2014). He has also won Gold, Silver and Bronze Medals at several International and local Conferences.
Plenary 5 Do’s and Don'ts in Publishing High Impact Research Output Abstract Publishing of high impact research output in a high impact factor journal is an effective strategy for enhancing the image for the Institution. For the researchers, it increases the citations frequency and career prospects. However, high impact journals seek high quality manuscripts. This paper highlights the do and don’ts in its submission. Do select a journal where your article fits its scope and objectives. Ensure your article has sound methodology, been proof read and written in good English language using short sentences. If you lack proficiency in the English language, get someone who is proficient in the language or English language editing professional to proof read and edit the article. Instructions to authors vary from journal to journal. It is vital to adhere to their guidelines, should not be a duplicate submission and avoid plagiarism. Title should be short, simple and eye catching. Writing a good abstract is crucial. The introduction must clearly establish the need for the study. The methodology must be stated in detail. The data must be presented in a logical sequence, appropriately interpretated and within the scope and objectives of the study. The tables and figures must be of high quality and self- explanatory. The discussion must be comprehensive and current. The conclusion must be based on its objectives. Cite the key scientific publications on which your research is based. It’s useful to have a senior co-author. The cover letter to the Editor is very important and should convince your editor that your article deserves to be published. Do not submit articles where the methods used are: not appropriate to meet the objectives, sample size is inadequate, response rate and sampling technique is poor , with too much missing data and analysis is inappropriate. Do not irritate or argue with a reviewer and address each of the comments from the reviewers. Look at negative reviews as opportunities for improvement.
PLENARY 6 Professor Dr. Lai Nai Ming M.B.B.S. (Hons) (Queensland), MRCP (UK), MRCPCH, AM (Malaysia) Professor of Paediatrics and Director of Clinical Campus, Coordinator, Senior Clerkship programme and Paediatrics Discipline, Member, Human Research and Ethics Review Board, Senate member, [Taylor’s University School of Medicine, Malaysia] Visiting Consultant Paediatrician, Hospital Sungai Buloh and Hospital Bentong, Malaysia. Adjunct Professor (Research), Monash University School of Pharmacy, Malaysia. NATIONAL AND INTERNATIONAL RESEARCH ROLES 1. Author in over 25 Cochrane systematic reviews at various stages of development with multi-national collaboration. Leading author in 12 reviews involving multinational collaboration. 2. Trainer, systematic review methods, National Institute of Health, Ministry of Health, Malaysia – supervised the development of over 12 Cochrane systematic reviews by the Institute for Medical Research, National Institute of Health, Malaysia since 2012. 3. Consultant, Malaysian Health Research Priority Setting Exercise 2021-2025. 4. Trainer, Cochrane systematic review, Cochrane Australasian Centre since 2006 (0ne of two earliest Cochrane trainers in Malaysia). 5. Advisor and reviewer, British Medical Journal (BMJ), Practice Series: Uncertainties and Change 6. Associate Editor, Cochrane Neonatal Review group and Cochrane Clinical Answers. 7. Editor, Cochrane Malay Translation Initiative (edited over 100 Cochrane review summaries to-date). 8. Member of the Journal Editorial Board: Pediatric Drugs (JIF 3.0), Systematic Reviews 9. Clinical quality assurance personnel and annotator, Cochrane Linked Data Project (a pioneering project in evidence pipeline funded by the Gates Foundation). 10. Purple screener (highest band), Cochrane Crowd (screened over 3000 abstracts) 11. Academic associate, SEA-ORCHID (South East Asian Optimising Reproductive and Child Health Outcomes in Developing Countries) Project (2006-2009). 12. Core team in forecasting COVID hospitalized and ICU cases using machine learning for Institute for Clinical Research, National Institute of Health, Ministry of Health, Malaysia. 13.Reviewer of research protocols: Malaysian National Medical Research Registry (NMRR).
Plenary 6 The Use of Machine Learning in Health Research : How Far Have We Come? Abstract Artificial Intelligence (AI) made its first defined shape in 1956 by mathematician Alan Turing in the form of a computer that deciphered codes, and in 1959, Arthur Samuel, another pioneer of AI, defined machine learning as a field of study that enables computers to continuously learn without being explicitly programmed. Six decades on, ML is now an integral branch of AI that harnesses the use of computer technologies to handle data, using sophisticated formulae known as algorithms to solve problems that require high intelligence with far more efficiency and consistency than any individual or team of human beings. With the explosion of data, the use of ML is rapidly expanding in practice and research across all fields, including Health, in the domains of diagnosis, prediction, therapeutics and quality improvement, among others. In this talk, the speaker shares his experiences in examining the use of ML in clinical practice in the field of Neonatal Medicine, in Health Education including teaching-learning and assessment, and in systematic review, a form of research that is data-intensive. He demonstrates how ML applications work in systematic review and forecasting, and introduces Cochrane Crowd, an example of an initiative that signifies the symbiotic relationship between machine and human’s global presence in deciphering the sea of literature and arranging them in groups that can be accessed easier by researcher, practitioners and consumers.
PLENARY 7 Dr. Kuldip Kaur A/P Prem Singh K.M.N MBBS (Manipal), MPH (UM), MHA (UM), CMIA (NIOSH) Director of Sungai Buloh Hospital, Selangor. Dr. Kuldip Kaur A / P Prem Singh is a certified medical officer and hospital administrator with excellent leadership qualities. She has obtained her Masters of Hospital Administration and Masters of Public Health. She has held the position of Deputy Director of Kuala Lumpur Hospital from May 2016 to 9 September 2019, and since 10 September 2019 as DirectorDoifreScutnogra,iHBouslophitaHlosSpuintagl,aSi eBlaunlogohr. Sungai Buloh Hospital which has been declared aascothmeppr[eIrNhimeSnaEsrRiyvTeanDtrdEaSnaIsdGfmoNrimAttTianItOgioNnh]otsopitthael for COVID-19 cases in Malaysia has undergone standard of operation and administration of the hospital. Dr Kuldip as the director has taken on a heavy responsibility in coordinating and managing all needs successfully to ensure the care to all patients is provided at an optimal level. Dr Kuldip's administration was an admirable feat. Dr. Kuldip has also contributed to the publication of 2 articles related to COVID namely Key Strategies In The Pandemic Preparedness as a COVID-19 Hospital, Perspectives From Sungai Buloh Hospital published by NIH and e-poster: Surge Capacity Dynamic at a COVID-19 Designated Hospital in Malaysia. Dr. Kuldip was also invited to give a talk at the Public Health Lane - Leadership Challenges in Managing Hospital during Pandemic COVID-19 for the 8th National Table Top Exercise and Communication in Disaster Medicine (TOPCOM 2020) on 26 August 2020 at UiTM Selayang National Conference for Clinical Research (NCCR) 2020 entitled Conference of Very Important Disease (COVID-19). Awards Recently Dr Kuldip has received recognition from British Publishing House Ltd and has been listed in the British Pedia book “Successful People in Malaysia” - 3rd Edition Encyclopedia for highly accredited personalities. Apart from that, she also received an invitation from Tatler Asia (Malaysia) Sdn.Bhd. to be interviewed which was published in the magazine for successful personality figure for 2021. Dr Kuldip was also interviewed by The Bigger Picture BFM Radio on her success in administering and managing Sungai Buloh Hospital during the COVID-19 pandemic. [insert awards/ achievement]
Plenary 7 Creating a Risk-Free Hospital Environment for Patients, Healthcare Workforce and Visitors through Technology Abstract Patient healthcare and management has taken leaps and bounds in advancement with the myriad technological innovations available to us now. The COVID-19 pandemic, while initially a setback, proved to be a springboard for the adoption and adaptation of cutting-edge technology that is crucial to our survival as a species. Examples of such are MySejahtera, vaccine production, genomic studies, contact tracing devices, alternative and green modes of transportation, increasing use of contactless food delivery services, and many more. The main challenges to hospital service providers are to integrate digital healthcare technologies into traditional hospital services with the aim to create a transparent and highly efficient healthcare system without walls or barriers. Hospital executives should be planning on how to integrate technology into newly built facilities and retrofit older facilities to enable a seamless integration between all components in healthcare services. As a healthcare administrator, minimization of patient safety-related risks is myforemost priority. While the benefits of health information technology are legion and can be used to enhance patient safety to an unprecedented level, I believe we should proceed with caution to ensure that patient welfare is our utmost priority, whilst also upgrading our services alongside our healthcare technology. The spread of COVID-19 stretched healthcare operational systems to their limits not only in Malaysia, but worldwide as well. Shortages and shortfalls had to be swiftly addressed, and as the director of the main COVID-19 hospital, the speaker has had a wealth of experience optimizing and modernizing response mechanisms. The speaker will share examples of improvements made for crisis response during the peak of the COVID-19 pandemic, for example, centralized clinical command centers, hospital dashboards, virtual conferences, virtual learning, and many more. The speaker will also share some of the roles that a healthcare leader must focus on to prepare an organization for the adoption and use of future technology as well as readiness of organizational capabilities for long-term success. Technology for healthcare must be balanced by an appropriate level of human clinical expertise for final decision-making to ensure that patients receive high quality and safe care.
PLENARY 8 Ms. Audrey Ooi Head of Business Development, Clinical Research Malaysia (CRM) Master’s Degree in Medical Science, University of Malaya Head of Business Development, Clinical Research Malaysia (CRM) Head of Business Development, Clinical Research Malaysia Feb 2019 – Feb 2020 - Business Development Manager, Clinical Research Malaysia May 2018 – Jan 2019 - Associate Business Development Manager, Clinical Research Malaysia Mar 2014 – May 2018 - Senior Business Development Executive, Clinical Research Malaysia Apr 2012 – Mar 2014 - Medical Writer Apr 2011 – Apr 2012 - Medical Writer, MediTech Media Awards Recipient of CRM CEO Award Current Programme Committee and Session Chair for DIA-CoRE Singapore Annual Meeting
Plenary 8 Sponsor Research in Malaysia : The way Forward Abstract Since 2012, Malaysia has conducted over 1900 sponsored research in various therapeutic areas. In 2021, Malaysia has moved up the leaderboard, placing itself second among Southeast Asia countries in terms of the volume of sponsored research. Many fruitful collaborations were formed in the last few years and the achievements of investigators in patient recruitment has been acknowledged by global sponsors and contract research organizations. In progressing forward, this talk will focus on three areas to propel the clinical research industry forward; enhancing First-in-Human (FIH) capabilities, expanding medical device clinical research and opportunities to tap into decentralized clinical trials.
PLENARY 9 Professor Dr. Goh Bak Leong B.Med.Sc(UKM), MD, MRCP(UK), FRCP(Glasg), FAMM Senior Consultant Nephrologist Head of Nephrology Department and Clinical Research Centre, Hospital Serdang Prof. Dr. Goh is a Senior Consultant Nephrologist. He is the Head of Nephrology Department and Clinical Research Centre, Hospital Serdang. He is an internationally recognised expert in interventional nephrology. He has published numerous original articles in international peer-reviewed journals in the field of general nephrology, dialysis and transplantation. He has presented a great number of scientific papers in international meetings and congresses. He was the Local Chair of the World Congress of Nephrology 2022 in Kuala Lumpur (WCN’22) and the Co-Chair of 17th Congress of the Asian Society of Transplantation (CAST 2021). He is also the Editor of Malaysian Dialysis & Transplant Registry. He is instrumental in introducing nephrologist initiated PD catheter insertion programme in Malaysia and many neighbouring countries. He has served as a member of tWIrnaodinrokenirnesgoAifawPPaa DurrdnttydsoeotrhneISPnPDeDpAhcrAocseliosagsnisGtCsuhifdarepoltmienreAssfieaalnloPdwascahilfsiiopc dedicated as an international such as Singapore, Brunei, programme.
Plenary 9 Utilisation of National Registry in Clinical Research in Malaysia ABSTRACT Registries provide consistent data for defined populations and can be used to support the study of the determinants and manifestations of disease and provide a picture of the natural history, outcomes of treatment, and experiences of individuals with a given condition or exposure. The use of disease registries for clinical studies has become increasingly common and has led to advancements in the understanding of many disease processes. The availability of demographic and disease characteristic data on large patient populations, coupled with the minimal cost and relative speed of conducting retrospective investigations, provide an attractive alternative to original data collection. However, one must be aware of the limitations inherent to the data collection process for registry which may result in the reduction of generalizability and introduce bias. One of the most important activities with greatest impact on the field of nephrology in this country is the formation of National Renal Registry, which was initially started by the pioneering nephrologists and paramedics in Hospital Kuala Lumpur. This was subsequently adopted by Malaysian Society of Nephrology which is the umbrella body to better represent the nephrology and dialysis communities for the whole country. The idea of a National Dialysis and Transplant Registry was mooted in the late 80’s and early 90’s with the purpose of formally looking at the data and evaluating the performance and outcomes in treating patients with end stage kidney disease. This was an important effort taken by the early pioneers who believed in continuous auditing and assessing the quality of care, besides providing invaluable information to health care providers, policy makers as well as industries. The pioneering nephrologists were keenly aware that the high cost of dialysis will come under close scrutiny of the public and policy makers due to the ever escalating cost of health care and budgetary constraints. This was coupled with the rapid expansion of private and NGO haemodilaysis facilities. Concerns about the quality and standards of treatment provided can only be reliably monitor with good and reliable data such as NRR. The first NRR Report published in 1993 was mainly focused on the dialysis programme run by Ministry of Health. In the subsequent years, data from all dialysis units in the private, NGOs and public sectors were collected to mark the beginning of a truly “National” renal registry.
MBBS (UM), Rebailitative Medicine, (UM), Fellowship in Pediatric Rehabilitation (Adelaide) Rehabilitation Physician and Head of CRC, Hospital Rehabilitasi Cheras M.B.B.S. (Hons) (Queensland), MRCP (UK), MRCPCH, AM (Malaysia) Director of Clinical Campus, School of Medicine, Taylor’s University, Sungai Buloh MD M.Comm. Med PhD Universiti Kebangsaan Malaysia Department of Community Health, Faculty of Medicine Universiti Kebangsaan Malaysia
MBBS (Mal), Master Paediatric (Mal), Paediatric Respiratory Fellowship programme (MOH, Malaysia) Paediatric Respiratory Consultant and Head CRC, Hospital Tunku Azizah Kuala Lumpur (HTAKL) Master of Obstetrics and Gynaecology, UNIVERSITY OF MALAYA, MalaysiaBachelor of Medicine and Bachelor of Surgery (MBBS), UNIVERSITY OF MALAYA, Malaysia Consultant Gynaecological Oncologist, School of Medicine, Taylor’s University, Sungai Buloh Community Medicine DepartmPhD (IMU), Dip. Teaching & Training (Cambridge),M. Ind Safety Mgmt (UKM), Postgrad Dip. Ind Safety Mgmt (UKM),RN, CCN.ent, International Medical University (IMU) Head, Institute for Health Systems Research (IHSR), National Institutes of Health (NIH) MD. MMed(Psych). PhD Consultant Psychiatrist, Associate Professor in Medicine (Psychiatry) Universiti Teknologi MARA (UiTM) Sungai Buloh PhD in Medical Sciences, TOHOKU UNIVERSITY JAPAN, Japan Master of Science (Medical Sciences) Bachelor of Science (Hons) Biomedical Sciences, UNIVERSITY PUTRA MALAYSIA, Malaysia Senior Lecturer, School Of Bioscience, Faculty of Health & Medical Sciences, Taylor’s University
1. 2. 3. 4.
oral Syazarin Fidhora Nasution Chromosomal Abnormalities in Chronic Lymphocytic Leukaemia Patients Treated in Hospital Ampang, Selangor Normawati Ahmad Effect of Health Education on the Knowledge, Attitude, and Behaviour of Healthy Snack Choices in School Among Students of Sekolah Indonesia, Kuala lumpur Chong Siew Lian A Real-World Study Of End Tyrosine Kinase Inhibitor In Chronic Myeloid Leukaemia (EnTIC) In Malaysia Lau Mei Siu A Systematic Review and Meta-Analysis on Herbal Medicine for Allergic Rhinitis. Nur Izati Binti Mustapa Evaluation Of The FilmArray Blood Culture Identification 2 Panel (BCID 2) compared to direct MALDI Biotyper Sepsityper (MBT Sepsityper) Identification For Rapid Pathogens Identification In Pathology Department Hospital Sungai Buloh (HSgB) Monica Francise Xavier Cognitive Stimulation Therapy mild to moderate dementia Ho Wan Yi Post COVID-19 Catatonia: Stuporous state in COVID-19 Infection Usha Sundralingam Gut microbiota circumvents the oral bioavailability challenges of medicinal herbal compounds : a scoping review Noor Muhammad Azlan Shah B Atan Kounis syndrome – a silent killer under the blanket Tan Ju Nee (Replacing Ms Koh Hui Moon) Safety Of Favipiravir In COVID-19 Patients with End Stage Renal Disease Fatimah Az Zaharah Binti Suhaimi Early hospital discharge and unplanned hospital readmission following discharge among general paediatric patients in children's hospital Adam Ashraf Bin Ja'afer Evaluation on The Optimal Vancomycin Therapeutic Drug Monitoring Using Area Under the Curve Against Trough Method in The National Infectious Disease Centre, Malaysia Mohd Ishtiaq Bin Anasir RT-PCR-Based Assays to Detect SARS-CoV-2 VOC Omicron Among International Travellers Arriving in Kuala Lumpur, November to December 2021. Hashvina Sukesh Mortality Rate and Associated Risk Factors in Hospitalised Covid-19 Patients with Kidney Disease Muhammad Nazim bin Othman Quadriceps Tendon Rupture in an End-Stage Renal Failure Patient Mistaken for a Soft Tissue Injury. A Case Report. Tanusha a/p Kunju Forgotten But Not Disappeared : Erythropoiesis Stimulating Agent Induced Pure Red Cell Aplasia Hashvina Sukesh Mortality Rate and Associated Risk Factors in Hospitalised Covid-19 Patients with Kidney Disease Muhammad Nazim bin Othman Quadriceps Tendon Rupture in an End-Stage Renal Failure Patient Mistaken for a Soft Tissue Injury. A Case Report. Tanusha a/p Kunju Forgotten But Not Disappeared : Erythropoiesis Stimulating Agent Induced Pure Red Cell Aplasia Aminatul Alisya Binti Ahmad Saifuddin “Spuriously Raised Serum Creatinine, Why?” Siti Aminah Binti Rodzlan Akib Rett Syndrome - Beyond the Ordinary Stereotypies in Autism Syamsul azwan bin abdullah A Catastrophic Case of MIS-C With Small Bowel Obstruction Hairul Anuar Bin Mahat Diagnostic Dilemma In Febrile Children: MIS-C versus dengue fever
oraEVElNT -&pLINKoS ster Nurul Sakinah Binti Anuar Evaluating the Risks of Adverse Maternal and Neonatal Outcomes among Unvaccinated Pregnant Mothers Admitted with COVID-19 in Ampang Hospital, Malaysia Edre Bin Mohammad Aidid Digital Epidemic Detection & Action (DETect): Development and validation of a mHealth Application for Empowering University Community COVID-19 Management Tan Wai Leong Carbapenem Stewardship Program: Impact on Carbapenem Usage & Patient's Clinical Outcome Tanessri A/P Muni Peragas Aromatic Spices Harbour Potential Novel Antibacterial Compounds against ESKAPE Pathogens Salihah Binti Muda Elucidating the sensitivity and specificity of RT-PCR and RTK-Antigen Test in diagnosing COVID-19 status in Hospital Shah Alam Abdullah Arief bin Aminuddin Seizure In Acute COVID-19 infection: Not just a meningoenchaphalitis Rebecca Jennifer Mary Louis Recurrence rate of ocular surface squamous neoplasia post wide excision, cryotherapy and post operative Mitomycin C Nur Adileen Bt Mohd Adam Vailaidam Frailty Assessment In The Emergency Department To Predict Moratlity And Morbidity In Older Adult Patients Admitting With Sepsis. Dr Moventhiran Predictors Of The Length Of Stay In An Intensive Care Unit And The Intracranial Pressure In Severe Traumatic Brain Injury Muhd Irfan Bukhari Bin Ahmad Nazri Biomarkers for Glutaric Aciduria Type 1 on High Risk Screening by Tandem Mass Spectrometry Norvena Binti Hisyam The Descriptive Study of Monitoring the Utilisation of Pharmacy Value-Added Services in Melaka Public Health Facilities Before and During the COVID-19 Pandemic Siti Romaino Mohd Nor Factors Associated with Tuberculosis (TB) Treatment Success among Tuberculosis (TB) and Human Immunodeficiency Virus (HIV) Co-Infected Patients in Kelantan Khairatul Nainey binti Kamaruddin The Use of Oral Complementary and Alternative Medicine Among Patients with Metabolic Syndrome in a University Primary Care Clinic Nur Amalina Binti Yusoff Audit on Uncollected Results during eHIS Downtime in Hospital Sungai Buloh Thiviya a/p Muthusamy Otorhinolaryngology-related referral for COVID-19 patients in intensive care unit (ICU): Urban district hospital experience Satya Tamilselvam COVID-19 Category during Period of Delta and Omicron Predominance in Malaysia: A Descriptive Study Wong Chun Mun Incidence of Proteinuria and Microscopic Hematuria in Hospitalized COVID-19 infected patients: A single center experience. Sze Xun Quan Home Based Peritoneal Dialysis Training During Covid-19 era: A Single Centre Experience
oral-poster Nordiana Binti Ab Manan A case report on acute necrotizing encephalopathy in association with COVID-19 infection Choong Kah Lai Rare Case of Breast Adenoid Cystic Carcinoma: Radio-Pathological Correlation Thinesh A/L Elangkovan Nasogastric tube entanglement in a nine months old Down's syndrome child: A case study Nur Malina binti Mat Reffien Association between epilepsy and gluten sensitivity based on HLA- DQ genotyping together with coeliac disease related antibody. Amitha Na Sherng Lhung Left Basal Ganglia Bleed Secondary to Hypertensive Emergency Muhammad Adam Bin Zainuddin Measuring EVD Trajectory Using Smartphone: A Case Report Laavanya Rajendran Facial nerve palsy as a presentation of Covid 19 in a child, a case report Yusanita Binti Jamalut Eikenella corrodens necrotising myositis in an immunocompetent adolescent. Ummul Nabilah Binti Shafie Ballantyne Syndrome Nur Atika Pitri Binti Siwan Case report : Unseen Side of Caesarean Section Hani binti Mohamed When tumor gets on your nerves - nasolabial schwannoma Amirah Atifah (Early Bird) Extremely Rare Case of a Giant Cell Tumor of Sphenoid Sinus with Aggressive lesion Involving Skull Region. Assoc. Prof. Dr. Eugene Leong A Concept Paper : Towards Healthier Mature Women – A RedBook for Mature Women 45 Years and Above ( RBMW ). Cheong John Yee Refusal to Walk Post Covid-19 in a Child with Cerebral Palsy and Rehabilitation Intervention Goh Hui Yin The Classical Internal Limiting Membrane Drape Sign Wong Soon Kuen A case report of paediatric intraventricular astrocytic tumour Dewaraj Velayudhan An analysis of the types of skull fractures and intracranial haemorrhages found in autopsies of road traffic accident victims in the year 2015-2017 and a comparison with a previous study done 20 years ago (1995-1997); in Manipal; a town in southern part of India
poster Hakimah Khani Binti Suhaimi Factors Associated With Specific Physical Activity Advice Delivered To Patients Among Primary Care Doctors In Klang Valley, Malaysia. Siti Sabrina binti Kamarudin Perspective of Mothers’ Experience with PPD and MHealth Intervention:A Systematic Qualitative Review Husaini Amin bin Masri COVID-19 Infection Severity in Hospital Sungai Buloh Healthcare Workers in Relation to Their Vaccination Status. Ng Poh Lee Geetha Impact of Pharmacists’ Interventions on the Utilization of Guideline-Directed Medical Therapy and Clinical Outcomes in the Heart Failure Frequent Flyer Programme HTAR KLANG Vaisnevee a/p Sugumar Characterization Deep Eutetic Solvents For Optimal Transdermal Drug Delivery Norsuhaila Binti Sha'ari Traditional and Complementary Medicine (T&CM) usage among Cancer Patients in Ministry of Health Hospitals Malaysia : A Descriptive Study Chin Wen Xin The Epidemiology Of Surgically Managed Brain Tumours In Selangor Raihana Asila binti A Kadir Routine Screening of Dengue and COVID-19 RTK for Non Critical Emergency Patients with Acute Febrile Illness Chiun pei zhi Short-term clinical outcomes of open repair of myelomeningocele from 2015-2022 : Hospital Sungai Buloh Syarifah Nurul Ain bt Syed Badaruddin COVID-19 Hospitalisation during Period of Delta and Omicron Predominance in Malaysia : A Descriptive Study Salina Binti Mohamed Sukur Serotypes and beta-lactamases-producing Haemophilus influenzae isolated from children attending childcare services in Kuala Lumpur post vaccination era Kamal Haikal Bin Mat Rabi The Malaysian Poliovirus Eradication Effort And Experience From The 2019 Polio Outbreak: Strengthening The Implementation Of The Potentially Infectious Materials, Poliovirus (PIM) Regulations In Poliovirus Surveillance And Research Programs. Tharmini Ravi Thromboembolic complication among COVID-19 patients in the intensive care unit (ICU): a single-centre study from a Malaysian perspective Song Chan Hoong Long-Term Renal Outcome of Living Kidney Donors: A Single Centre Experience Shafiq Eiman Bin Abdul Razak CRPS in central cord syndrome : A steroid solution to the integrated multidisciplinary management Rifhan Nabilah Binti Sudirman Effectiveness of Rapid Test Kit Antigen (RTK-Ag) as a Screening Test for COVID-19 in the Emergency Department (ED) Teh Ping An Outcome of Decompressive Craniectomy in Supratentorial Large Territory Acute Infarction Chong Pei Feng Review of Discharge Medications At A Post COVID Care Clinic Lim Wan Xin Role of Environmental Cleaning in the Control of Multidrug-Resistant Acinetobacter Baumannii (MRAB) Outbreaks in an Intensive Care Unit (ICU). Suriya Kala Balachandran COVID-19 Mortality rate during period of delta and omicron predominance in Malaysia : A descriptive study Uvanesan Kathiravelu Incidence and outcome of cytomegalovirus in kidney transplant recipients: A single center experience. Nur Farahin Binti Zainal Abidin Correlation Between SARS-CoV-2 RTK Antigen From Saliva with SARS-CoV-2 RT- PCR From October 2021 Till April 2022 In Hospital Sungai Buloh (HSgB) Ong Yu Chen Risk Factors and Impact Of Delayed Graft Function Post Deceased Donor Kidney Transplant: A Single Centre Experience Naadhiya A/P Siva Kumar Changing Mindsets toward Hand Hygiene (HH) Compliance in a Tertiary Hospital through an Innovative Hand Hygiene Campaign (HHC) Azura Mohd Noor Latent Tuberculosis – What should we know and what should we do? Wan Nur Syamimi Binti Wan Mohamad Darani Community Case Report: A Cross-Border Technology-Driven Health Promotion Leow Mei Lian “Doing Research with Refugees the Ethical Way” - Innovative Way to Promote Refugee Research Ethics During COVID-19 Pandemic Wong Yik Hong Tacrolimus metabolism and impact on graft function, a single center experience.
DISPLAY poster Siti Sabrina binti Kamarudin Development of MHealth Intervention for Mothers with Postpartum Depression: A Protocol Assoc. Prof. Dr. Eugene Leong A Concept Paper : Nano-Endoscopy – Future Future Future Mini-Guided Laparoscopy. Assoc. Prof. Dr. Eugene Leong A Concept Paper : Extended Routine Antenatal Booking Blood Tests ( Extended ABB ). Chong Siew Lian Molecular Interrogation of Chronic Myeloid Leukaemia Patients Who Failed Second Generation Tyrosine Kinase Inhibitor Using Next Generation Sequencing. Chong Siew Lian A Single Centre Evaluation of Sysmex XN-HPC For The Enumeration of CD34+ Cell In PBSC. Siti Hajar Nurdiana Complete Tracheal Ring- Diagnostic Dilemma of Hypercarbia in Ventilated Children Zailatul Hani Binti Mohamad Yadzir Do Women Living With HIV (WLHIV) Experience Stigma And Discrimination When Accessing Sexual And Reproductive Health (SRH) Services In Government Health Facilities In Malaysia? Syazarin Fidhora Nasution Real World Outcome of Chronic Lymphocytic Leukaemia Patients Treated with Venetoclax in Hospital Ampang, Selangor Noor Muhammad Azlan Shah B Atan The Impact Of Sacubitril/Valsartan On Reverse Cardiac Remodelling As Comparison With Perindopril Among Patient With Heart Failure With Reduced Ejection Fraction Naadhiya A/P Siva Kumar Outbreak of Multidrug-Resistant Acinetobacter Baumannii (MRAB) in a Tertiary Care Intensive Care Unit (ICU) during the COVID-19 Pandemic: A Multimodal Strategic Approach Nur Malina binti Mat Reffien Chiari I Malformation with extensive synringomyelia – A rare cause of bilateral foot drop Siti Romaino Mohd Nor Development and Validation of New Questionnaire on Knowledge and Attitude (QKA) Towards TB Treatment among TB/HIV Co-Infected Patients in Kelantan Nur Amalina Binti Yusoff A Rare Case of Rhabdomyolisis in COVID-19 Wong Chun Mun Lobulated kidneys- A mimicker of renal tumour Siti Hajar Nurdiana A Rare Case of a Giant Ethmoid Sinus Osteoma with Orbital Extension Nesha Rajendram Office based non-invasive diagnostic technique for acquired tracheoesophageal fistula
Vol 77 Supplement 3, September 2022 - 9th Selangor Research Conference (SRC) http://www.e- mjm.org/2022/v77s3/index.html
DR THARMINI DR SURIYA KALA DR SATYA DR SHAFIQ EIMAN MEDICAL OFFICER MEDICAL OFFICER MEDICAL OFFICER MEDICAL OFFICER DR SWARNA LATA DR LIEW BOON SENG DR SYARIFAH ADMIN MANAGER HEAD OF UNIT NURUL AIN MEDICAL OFFICER SN NORHAFIZA HALIM SITI FARAHAMINAH BINTI MUHAMMAD NUR ALYA AFRINA BINTI STAFF NURSE HASSAN KHAIRULAZMIR BIN NAIP MOHD NOOR RESEARCH OFFICER RESEARCH OFFICER ADMIN ASSISTANT
07 & 08 SEPTEMBER 2022
'INNOVATIVE WITH THE LESS PRIVILEGED AMONGST US IN MIND\"
Search
